Navigation Links
Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcano's VH(R) IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks
Date:9/24/2009

ase is the same. We cannot predict a patient's risk of having future cardiac events by looking at a 2-D, black-and-white image of the arterial lumen. Available tools like IVUS and VH(R) IVUS that look at the quantity, location and type of disease and not just the narrowing of the vessel improve our ability to determine the likelihood of a particular lesion type to cause an event. PROSPECT has shown the ability to use VH and grayscale IVUS to classify different lesion types per the PROSPECT definitions. This trial highlights not only the potential of Volcano's VH(R) IVUS, but just as important, the limitations of using angiography alone."

VH(R) IVUS uses advanced spectral analysis of the ultrasound signal to classify atherosclerotic disease into different plaque components. By using these four plaque components, the PROSPECT investigators grouped the baseline lesions into five distinct lesion types; Fibrotic, Fibro-Calcific, Pathological Intimal Thickening, Thick-Cap Fibroatheroma and Thin-Cap Fibroatheroma, in order of hypothesized risk.

PROSPECT Results

The PROSPECT event data presented today demonstrates that the measurements made using grayscale and VH(R) IVUS did have a statistically significant impact in determining the likelihood of a particular lesion type to cause an event. The highest risk PROSPECT plaque type being VH Thin Cap Fibroatheromas with a minimum lumen area of less than or equal to 4mm(2) and a plaque burden greater than or equal to 70%. All three of these important parameters (each an independent predictor) when combined showed that the particular lesion imaged at baseline had a 17.2% chance of causing an event within three years. It is important to note that current practice of using angiography alone cannot measure plaque burden or the presence of VH-TCFAs, which were the two most significant predictors of lesion risk in the study. These measures can only be collected using Volcano's prop
'/>"/>

SOURCE Volcano Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Video: New Clinical Trial Results Show Germ-Killing Action of LISTERINE(R) Antiseptic Kills Germs in the Mouth Before They Travel to the Bloodstream
2. Volcano Corporation Praises FAME Study Results
3. Dynatronics to Release Fourth Quarter and Year-end Results Friday, September 25, 2009; Conference Call Set for 12:30 p.m. ET
4. InVitria Presents Zap-CHO Performance Results at PEACe Conference
5. Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results
6. Assurant to Announce 2009 Third Quarter Results Oct. 28, 2009 and Host Webcast Conference Call Oct. 29
7. SpectraScience Announces Results of Annual Shareholder Meeting
8. One-year results from Horizons-AMI trial reported at TCT 2009
9. New type of sirolimus-eluting stent demonstrates superior results
10. Details Emerge About Approach, Results of First US Face Transplant
11. Instrumentation Laboratory Announces Passion & Results Award Winners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2014)... Aliso Viejo, California (PRWEB) September 14, 2014 ... Pixel Film Studios, announces the production of the Flip ... X . , "Flip Flop is a simple-to-use and ... professional themed video with ease in Final Cut Pro ... "With 48 camera options and On-Screen controls, the user ...
(Date:9/14/2014)... is an internationally well-known designer and leader in the ... of cocktail dresses under $100 . To attract ... the company is also providing big savings for its ... black formal gowns and so on. The current discount ... company’s senior spokesman says, “We are pleased to announce ...
(Date:9/13/2014)... 2014 Over the past five ... in Australia have shown signs of struggle. ... confectionery goods has caused Australian consumers to turn ... to IBISWorld industry analyst Ryan Lin. This trend ... of health consciousness, which has alerted the Australian ...
(Date:9/13/2014)... Ticket Down is a dependable source for ... group that originally formed in 1994 in Los Angeles, California, ... group had been anticipating a new album since 2012 when ... about the release of their new album, they will be ... worldwide tour beginning in the United States in February. The ...
(Date:9/13/2014)... September 13, 2014 Healthcare employers, ... manufacturers turn to operators in the Healthcare ... manage risk. “Over the past five years, demand ... advances in the healthcare sector and the changing ... Phillips. Moreover, the 2010 Patient Protection and Affordable ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Releases Flip Flop Theme for Final Cut Pro X Users 2Health News:UWDress.com: Elegant Cocktail Dresses Under $100 Now Offered 2Health News:Confectionery Manufacturing in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Confectionery Manufacturing in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 2Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 3Health News:Healthcare Consultants in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Healthcare Consultants in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... variant ups violence inclination, study finds , WEDNESDAY, June 17 (HealthDay ... for boys joining violent street gangs. But a new study finds ... part, in their genes. , Boys who have a variant of ... "warrior gene" -- are not only more likely to be in ...
... effective after heart attack and stroke , WEDNESDAY, June 17 ... the risk of stroke, heart attack and death in patients ... angina, a new trial shows. , Rivaroxaban is a pill ... In earlier studies, the drug was effective in preventing venous ...
... N.J., June 17 Nuvilex, Inc. (OTC Bulletin Board: ... that it has renewed its Master Distribution Agreement with ... and aesthetic solutions, for the distribution and sale of ... , The renewal is for one year and ...
... Sciences Category , , SUNNYVALE, Calif., June 17 ... ARAY ), a global leader in the field of radiosurgery, ... CEO, received the Ernst & Young Entrepreneur Of The Year(R) ... Northern California. According to Ernst & Young LLP, the ...
... , HERLEV, Denmark, June 17 A leading Danish cancer ... installing eight advanced radiotherapy treatment machines from Varian Medical Systems ... Herlev Hospital, to the north-west of Copenhagen, delivered ... patient using a Clinac(R) iX linear accelerator. , , ...
... Therapeutics, Inc. (OTC Bulletin Board: ECTE) announced today ... Handok Pharmaceuticals Co., Ltd. ("Handok"), the largest diabetes ... Echo granted Handok rights to develop, market, sell ... painless, needle-free, transdermal, continuous glucose monitoring ("tCGM") in ...
Cached Medicine News:Health News:Boys May Feel a Genetic Pull Toward Gangs 2Health News:New Anticoagulant Pill Works Well in Trial 2Health News:New Anticoagulant Pill Works Well in Trial 3Health News:Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream 2Health News:Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream 3Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 2Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 3Health News:Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital 2Health News:Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital 3Health News:Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System 2Health News:Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System 3Health News:Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System 4
(Date:9/12/2014)... 12, 2014 Sepsis is a life ... worldwide.  Education and awareness are fundamental to improving ... marks Sepsis Awareness Month and September 13 th ... Sepsis Alliance, "Sepsis, the body,s toxic reaction to ... every year, and thousands more are left with ...
(Date:9/11/2014)... , September 11, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/lqkmlx/radio_frequency ) has announced the ... Identification (RFID) Market in Healthcare (Tags, ... Industry Analysis, Size, Share, Growth, Trends ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:9/11/2014)... , Sept. 11, 2014 Array BioPharma Inc. ... focused on the discovery, development and commercialization of ... cancer, today announced the appointment of Victor ... Sandor will be responsible for leading clinical, medical ... portfolio, including binimetinib, a MEK inhibitor in Phase ...
Breaking Medicine Technology:Nanomix Supports Sepsis Awareness 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 3Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 2Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 3Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: